Form 8-K - Current report:
SEC Accession No. 0001193125-25-002920
Filing Date
2025-01-07
Accepted
2025-01-07 17:18:03
Documents
14
Period of Report
2025-01-07
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d909848d8k.htm   iXBRL 8-K 29471
  Complete submission text file 0001193125-25-002920.txt   191866

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA snse-20250107.xsd EX-101.SCH 3870
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE snse-20250107_def.xml EX-101.DEF 14095
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE snse-20250107_lab.xml EX-101.LAB 23424
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE snse-20250107_pre.xml EX-101.PRE 15128
17 EXTRACTED XBRL INSTANCE DOCUMENT d909848d8k_htm.xml XML 5603
Mailing Address 1405 RESEARCH BLVD, SUITE 125 ROCKVILLE MD 20850
Business Address 1405 RESEARCH BLVD, SUITE 125 ROCKVILLE MD 20850 (240) 243-8000
Sensei Biotherapeutics, Inc. (Filer) CIK: 0001829802 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39980 | Film No.: 25515733
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)